{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:11:57Z","timestamp":1787026317935,"version":"build-2736575974"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>As binary switches, RAS proteins switch to an ON\/OFF state during signaling and are on a leash under normal conditions. However, in RAS-related diseases such as cancer and RASopathies, mutations in the genes that regulate RAS signaling or the RAS itself permanently activate the RAS protein. The structural basis of this switch is well understood; however, the exact mechanisms by which RAS proteins are regulated are less clear. RAS\/MAPK syndromes are multisystem developmental disorders caused by germline mutations in genes associated with the RAS\/mitogen-activated protein kinase pathway, impacting 1 in 1,000\u20132,500 children. These include a variety of disorders such as Noonan syndrome (NS) and NS-related disorders (NSRD), such as cardio facio cutaneous (CFC) syndrome, Costello syndrome (CS), and NS with multiple lentigines (NSML, also known as LEOPARD syndrome). A frequent manifestation of cardiomyopathy (CM) and hypertrophic cardiomyopathy associated with RASopathies suggest that RASopathies could be a potential causative factor for CM. However, the current supporting evidence is sporadic and unclear. RASopathy-patients also display a broad spectrum of congenital heart disease (CHD). More than 15 genes encode components of the RAS\/MAPK signaling pathway that are essential for the cell cycle and play regulatory roles in proliferation, differentiation, growth, and metabolism. These genes are linked to the molecular genetic pathogenesis of these syndromes. However, genetic heterogeneity for a given syndrome on the one hand and alleles for multiple syndromes on the other make classification difficult in diagnosing RAS\/MAPK-related diseases. Although there is some genetic homogeneity in most RASopathies, several RASopathies are allelic diseases. This allelism points to the role of critical signaling nodes and sheds light on the overlap between these related syndromes. Even though considerable progress has been made in understanding the pathophysiology of RASopathy with the identification of causal mutations and the functional analysis of their pathophysiological consequences, there are still unidentified causal genes for many patients diagnosed with RASopathies.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1176828","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T03:03:55Z","timestamp":1689563035000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["RASopathies and cardiac manifestations"],"prefix":"10.3389","volume":"10","author":[{"given":"Nazia","family":"Hilal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangita","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","article-title":"The RASopathies: developmental syndromes of ras\/MAPK pathway dysregulation","volume":"19","author":"Tidyman","year":"2009","journal-title":"Curr Opin Genet Dev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies","volume":"14","author":"Rauen","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ppedcard.2015.01.002","article-title":"Cardiomyopathies in Noonan syndrome and the other RASopathies","volume":"39","author":"Gelb","year":"2015","journal-title":"Prog Pediatr Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/oxfordjournals.eurheartj.a061452","article-title":"The Noonan syndrome","volume":"4","author":"Sanchez-Cascos","year":"1983","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/s1357-2725(98)00002-8","article-title":"SHP-2, SH2-containing protein tyrosine phosphatase-2","volume":"30","author":"Stein-Gerlach","year":"1998","journal-title":"Int J Biochem Cell Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/excr.1999.4668","article-title":"Shp-2 tyrosine phosphatase: signaling one cell or many","volume":"253","author":"Feng","year":"1999","journal-title":"Exp Cell Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/adc.2006.104547","article-title":"The natural history of Noonan syndrome: a long-term follow-up study","volume":"92","author":"Shaw","year":"2007","journal-title":"Arch Dis Child"},{"key":"B8","first-page":"894","article-title":"Successful mitral valve plasty for mitral regurgitation combined with dilated cardiomyopathy in Noonan\u2019s syndrome","volume":"43","author":"Takazawa","year":"1995","journal-title":"Nihon Kyobu Geka Gakkai"},{"key":"B9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0167-5273(96)02713-1","article-title":"Dilated cardiomyopathy in Noonan\u2019s syndrome","volume":"56","author":"Yu","year":"1996","journal-title":"Int J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/hupa.2000.7635","article-title":"Dilated cardiomyopathy in Noonan\u2019s syndrome: a first autopsy case","volume":"31","author":"Kurose","year":"2000","journal-title":"Hum Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/ajmg.a.61072","article-title":"Prevalence of pathogenic and likely pathogenic variants in the RASopathy genes in patients who have had panel testing for cardiomyopathy","volume":"179","author":"Aljeaid","year":"2019","journal-title":"Am J Med Genet A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1750-1172-3-13","article-title":"Leopard syndrome","volume":"3","author":"Sarkozy","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.rec.2012.09.015","article-title":"LEOPARD Syndrome: a variant of Noonan syndrome strongly associated with hypertrophic cardiomyopathy","volume":"66","author":"Carcavilla","year":"2013","journal-title":"Rev Esp Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0178905","DOI":"10.1371\/journal.pone.0178905","article-title":"In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan syndrome with multiple lentigines-associated hypertrophic cardiomyopathy","volume":"12","author":"Wang","year":"2017","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1086\/504394","article-title":"Germline missense mutations affecting KRAS isoform B are associated with a severe Noonan syndrome phenotype","volume":"79","author":"Carta","year":"2006","journal-title":"Am J Hum Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jpeds.2011.05.024","article-title":"Spectrum of mutations in Noonan syndrome and their correlation with phenotypes","volume":"159","author":"Lee","year":"2011","journal-title":"J Pediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ng.497","article-title":"A restricted spectrum of NRAS mutations causes Noonan syndrome","volume":"42","author":"Cirstea","year":"2010","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajhg.2013.05.021","article-title":"Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS\/MAPK pathway syndrome","volume":"93","author":"Aoki","year":"2013","journal-title":"Am J Hum Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.0954-6820.1976.tb06712.x","article-title":"A comparative study of the effects of cholestyramine and neomycin in the treatment of type II hyperlipoproteinaemia","volume":"199","author":"Schade","year":"1976","journal-title":"Acta Med Scand"},{"key":"B20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/0092-8674(95)90498-0","article-title":"The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development","volume":"80","author":"Tang","year":"1995","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1128\/MCB.18.10.6075","article-title":"Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing shp-2 mutant cells","volume":"18","author":"Qu","year":"1998","journal-title":"Mol Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/73528","article-title":"Mice mutant for egfr and Shp2 have defective cardiac semilunar valvulogenesis","volume":"24","author":"Chen","year":"2000","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/74279","article-title":"The SH2 tyrosine phosphatase shp2 is required for mammalian limb development","volume":"24","author":"Saxton","year":"2000","journal-title":"Nat Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The \u2018Shp\u2019ing news: sH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/ng1926","article-title":"Germline gain-of-function mutations in SOS1 cause Noonan syndrome","volume":"39","author":"Roberts","year":"2007","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1006\/geno.1993.1421","article-title":"Mammalian homologues of the Drosophila son of sevenless gene map to murine chromosomes 17 and 12 and to human chromosomes 2 and 14, respectively","volume":"18","author":"Webb","year":"1993","journal-title":"Genomics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1086\/339689","article-title":"A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1","volume":"70","author":"Hart","year":"2002","journal-title":"Am J Hum Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/humu.21492","article-title":"SOS1 Mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations","volume":"32","author":"Lepri","year":"2011","journal-title":"Hum Mutat"},{"key":"B29","doi-asserted-by":"publisher","first-page":"pe36","DOI":"10.1126\/stke.2002.145.pe36","article-title":"The two hats of SOS","volume":"2002","author":"Nimnual","year":"2002","journal-title":"Sci STKE"},{"key":"B30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jmg.2007.051276","article-title":"SOS1 Is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome","volume":"44","author":"Zenker","year":"2007","journal-title":"J Med Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/ng1748","article-title":"Germline KRAS mutations cause Noonan syndrome","volume":"38","author":"Schubbert","year":"2006","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000134028","article-title":"Determination of the gene order of the three loci CD2, NGFB, and NRAS at human chromosome band 1p13 and refinement of their localisation at the subband level by fluorescence in situ hybridisation","volume":"70","author":"Mitchell","year":"1995","journal-title":"Cytogenet Cell Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1002\/ajmg.a.36722","article-title":"Further evidence of the importance of RIT1 in Noonan syndrome","author":"Bertola","year":"2014","journal-title":"Am J Med Genet A"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/ajmg.a.36646","article-title":"Contribution of RIT1 mutations to the pathogenesis of Noonan syndrome: four new cases and further evidence of heterogeneity","author":"Gos","year":"2014","journal-title":"Am J Med Genet A"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/ng2073","article-title":"Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy","volume":"39","author":"Pandit","year":"2007","journal-title":"Nat Genet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/ng2078","article-title":"Germline gain-of-function mutations in RAF1 cause Noonan syndrome","volume":"39","author":"Razzaque","year":"2007","journal-title":"Nat Genet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/humu.21187","article-title":"Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation","volume":"31","author":"Kobayashi","year":"2010","journal-title":"Hum Mutat"},{"key":"B38","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/s0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0960-9822(99)80164-x","article-title":"Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta","volume":"9","author":"Giroux","year":"1999","journal-title":"Curr Biol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/jmg.2007.050450","article-title":"Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS\/MAPK signalling pathway: genotype-phenotype relationships and overlap with costello syndrome","volume":"44","author":"Nava","year":"2007","journal-title":"J Med Genet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/jmedgenet-2015-103018","article-title":"Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome","volume":"52","author":"Yamamoto","year":"2015","journal-title":"J Med Genet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/ng.2855","article-title":"Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas","volume":"46","author":"Piotrowski","year":"2014","journal-title":"Nat Genet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ejhg.2014.115","article-title":"Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan syndrome","volume":"23","author":"Vissers","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1074\/jbc.M508017200","article-title":"A novel protease inhibitor of the alpha2-macroglobulin family expressed in the human epidermis","volume":"281","author":"Galliano","year":"2006","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11473","DOI":"10.1073\/pnas.1324128111","article-title":"Next-generation sequencing identifies rare variants associated with Noonan syndrome","volume":"111","author":"Chen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","article-title":"Incidence and mortality of neurofibromatosis: a total population study in Finland","volume":"135","author":"Uusitalo","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/35002593","article-title":"A neurofibromatosis-1-regulated pathway is required for learning in Drosophila","volume":"403","author":"Dasgupta","year":"2000","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.1523\/JNEUROSCI.23-26-08949.2003","article-title":"The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes","volume":"23","author":"Guo","year":"2003","journal-title":"J Neurosci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"714","DOI":"10.5543\/tkda.2015.27557","article-title":"Neurofibromatosis type 1 and cardiac manifestations","volume":"43","author":"\u0130ncecik","year":"2015","journal-title":"Turk Kardiyol Dern Ars"},{"key":"B50","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/cge.12072","article-title":"Cardiac characterization of 16 patients with large NF1 gene deletions","volume":"84","author":"Nguyen","year":"2013","journal-title":"Clin Genet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/genes10090675","article-title":"Prevalence, type, and molecular Spectrum of NF1 mutations in patients with neurofibromatosis type 1 and congenital heart disease","volume":"10","author":"Pinna","year":"2019","journal-title":"Genes (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1056\/NEJM198604173141603","article-title":"Long-term follow-up of von recklinghausen neurofibromatosis. Survival and malignant neoplasms","volume":"314","author":"S\u00f8rensen","year":"1986","journal-title":"N Engl J Med"},{"key":"B53","article-title":"Fibromuscular dysplasia","volume-title":"Statpearls","author":"Baradhi","year":"2022"},{"key":"B54","first-page":"310","article-title":"Fatal spontaneous retroperitoneal haemorrhage caused by von Recklinghausen\u2019s neurofibromatosis","volume":"27","author":"Keenan","year":"1982","journal-title":"J R Coll Surg Edinb"},{"key":"B55","first-page":"831","article-title":"Fatal spontaneous retroperitoneal hemorrhage in a patient with von Recklinghausen\u2019s disease. A case report","volume":"76","author":"Shelton","year":"1983","journal-title":"J Indiana State Med Assoc"},{"key":"B56","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1742-1241.1990.tb10202.x","article-title":"Recurrent near-fatal haemorrhage in von Recklinghausen\u2019s disease","volume":"44","author":"Poston","year":"1990","journal-title":"Br J Clin Pract"},{"key":"B57","article-title":"Neurofibromatosis 1","volume-title":"Genereviews\u00ae","author":"Friedman","year":"1993"},{"key":"B58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/1096-8628(20001113)95:2-108::aid-ajmg4%3E3.0.co;2-0","article-title":"Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1","volume":"95","author":"Friedman","year":"2000","journal-title":"Am J Med Genet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00125817-200205000-00002","article-title":"Cardiovascular disease in neurofibromatosis 1: report of the NF1 cardiovascular task force","volume":"4","author":"Lin","year":"2002","journal-title":"Genet Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1067\/mhj.2002.122121","article-title":"The heart in neurofibromatosis type 1: an echocardiographic study","volume":"143","author":"Tedesco","year":"2002","journal-title":"Am Heart J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"9658","DOI":"10.1073\/pnas.88.21.9658","article-title":"Identification of the neurofibromatosis type 1 gene product","volume":"88","author":"Gutmann","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jocn.2018.04.006","article-title":"Clinical characteristics and NF1 gene mutation analysis of three successive generations in three different Indian families with neurofibromatosis type 1 and peripheral nerve sheath tumours","volume":"53","author":"Prasad","year":"2018","journal-title":"J Clin Neurosci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jmedgenet-2013-102240","article-title":"ADAP2 In heart development: a candidate gene for the occurrence of cardiovascular malformations in NF1 microdeletion syndrome","volume":"51","author":"Venturin","year":"2014","journal-title":"J Med Genet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/jmg.2003.014761","article-title":"Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2","volume":"41","author":"Venturin","year":"2004","journal-title":"J Med Genet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.4081\/pr.2015.5955","article-title":"A novel Noonan syndrome RAF1 mutation: lethal course in a preterm infant","volume":"7","author":"Ratola","year":"2015","journal-title":"Pediatr Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ajmg.a.38569","article-title":"The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor","volume":"176","author":"Harms","year":"2018","journal-title":"Am J Med Genet A"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e250342","DOI":"10.1136\/bcr-2022-250342","article-title":"Male infant with Noonan syndrome with RAF-1 gene mutation who survived hypertrophic cardiomyopathy-induced fatal heart failure and uncontrollable arrhythmias","volume":"15","author":"Hagino","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s40001-022-00772-2","article-title":"Noonan syndrome with RAF1 gene mutations in a newborn with cerebral haemorrhage","volume":"27","author":"Lan","year":"2022","journal-title":"Eur J Med Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5734\/JGM.2019.16.1.1","article-title":"Noonan syndrome and RASopathies: clinical features, diagnosis and management","volume":"16","author":"Lee","year":"2019","journal-title":"J Genet Med,"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e210549","DOI":"10.1530\/EC-21-0549","article-title":"Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence","volume":"11","author":"Romano","year":"2022","journal-title":"Endocr Connect"},{"key":"B72","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13023-022-02195-y","article-title":"A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1","volume":"17","author":"Hamoy-Jimenez","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"12070","DOI":"10.1038\/s41598-020-68908-0","article-title":"Functional and morphological cardiovascular alterations associated with neurofibromatosis 1","volume":"10","author":"Cutruzzol\u00e0","year":"2020","journal-title":"Sci Rep"},{"key":"B74","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/chd.12102","article-title":"Cardiac findings in Noonan syndrome on long-term follow-up","volume":"9","author":"Colquitt","year":"2014","journal-title":"Congenit Heart Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hfc.2021.07.004","article-title":"Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management","volume":"18","author":"Lioncino","year":"2022","journal-title":"Heart Fail Clin"},{"key":"B76","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-019-1010-z","article-title":"Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort","volume":"14","author":"Chen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"915129","DOI":"10.3389\/fgene.2022.915129","article-title":"Cardiovascular abnormalities and gene mutations in children with Noonan syndrome","volume":"13","author":"Sun","year":"2022","journal-title":"Front Genet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1017\/S104795112200124X","article-title":"Cardiac features of Noonan syndrome in Japanese patients","volume":"33","author":"Ichikawa","year":"2023","journal-title":"Cardiol Young"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2023.01.012","article-title":"Risk of sudden death in patients with RASopathy hypertrophic cardiomyopathy","volume":"81","author":"Lynch","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41436-020-01093-7","article-title":"When to test fetuses for RASopathies? Proposition from a systematic analysis of 352 multicenter cases and a postnatal cohort","volume":"23","author":"Scott","year":"2021","journal-title":"Genet Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI44929","article-title":"MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e003327","DOI":"10.1161\/CIRCGEN.121.003327","article-title":"Molecular management of multifocal atrial tachycardia in Noonan\u2019s syndrome with MEK1\/2 inhibitor trametinib","volume":"14","author":"Meisner","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/genes13010006","article-title":"MEK Inhibition in a newborn with RAF1-associated Noonan syndrome ameliorates hypertrophic cardiomyopathy but is insufficient to revert pulmonary vascular disease","volume":"13","author":"Mussa","year":"2021","journal-title":"Genes (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e20200167","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"B86","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J Pediatr"},{"key":"B87","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ahj.2012.04.018","article-title":"Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the pediatric cardiomyopathy registry","volume":"164","author":"Wilkinson","year":"2012","journal-title":"Am Heart J"},{"key":"B88","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12920-022-01336-3","article-title":"RASopathies due to de novo pathogenic variants: clinical features, genetic findings and outcomes in nine neonates born with congenital heart defects","volume":"15","author":"Zheng","year":"2022","journal-title":"BMC Med Genomics"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1176828\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T03:04:01Z","timestamp":1689563041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1176828\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":88,"alternative-id":["10.3389\/fcvm.2023.1176828"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1176828","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"article-number":"1176828"}}